Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $18.6 million.

  • Zhengye Biotechnology Holding's Total Current Liabilities changed N/A to $18.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.6 million, marking a year-over-year change of. This contributed to the annual value of $18.9 million for FY2024, which is 1102.67% down from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Total Current Liabilities of $18.6 million as of Q2 2025.
  • Zhengye Biotechnology Holding's Total Current Liabilities' 5-year high stood at $20.9 million during Q4 2023, with a 5-year trough of $18.6 million in Q2 2025.
  • For the 3-year period, Zhengye Biotechnology Holding's Total Current Liabilities averaged around $19.5 million, with its median value being $18.9 million (2024).
  • Data for Zhengye Biotechnology Holding's Total Current Liabilities shows a peak YoY increase of 932.2% (in 2024) and a maximum YoY decrease of 932.2% (in 2024) over the last 5 years.
  • Over the past 3 years, Zhengye Biotechnology Holding's Total Current Liabilities (Quarter) stood at $20.9 million in 2023, then decreased by 9.32% to $18.9 million in 2024, then dropped by 1.48% to $18.6 million in 2025.
  • Its last three reported values are $18.6 million in Q2 2025, $18.9 million for Q4 2024, and $20.9 million during Q4 2023.